The observation that elevated sAML-related SAD values can be “normalized” by anti-proliferative treatment with rigosertib correlating with the disappearance of the small cell population with prominent levels of separase proteolytic activity makes the SAD value a conceivable new marker for disease monitoring in MDS. Here, ESPL1 is linked to myelodysplastic syndrome.